News coverage about Alphatec (NASDAQ:ATEC) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alphatec earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave media headlines about the medical technology company an impact score of 45.4738467586626 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
ATEC has been the subject of a number of research analyst reports. HC Wainwright set a $4.00 price target on Alphatec and gave the company a “buy” rating in a report on Tuesday, March 13th. Zacks Investment Research raised Alphatec from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd.
Shares of Alphatec stock remained flat at $$3.35 during trading on Monday. The company had a trading volume of 6,118 shares, compared to its average volume of 86,337. The company has a debt-to-equity ratio of -1.42, a current ratio of 2.23 and a quick ratio of 1.32. Alphatec has a fifty-two week low of $1.58 and a fifty-two week high of $4.27. The company has a market capitalization of $85.33, a PE ratio of -9.31 and a beta of 1.25.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/09/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-alphatec-atec-stock-price.html.
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.